Ann Am Thorac Soc

Tirzepatide may offer superior CV protection in patients with OSA and T2DM

August 6, 2025

In patients with OSA and T2DM, tirzepatide is associated with a greater reduction in CV risk than liraglutide or semaglutide, with additional benefit in reducing incident OSA vs. liraglutide.

Study details: A large retrospective cohort analysis used a global federated database to compare the real-world efficacy of tirzepatide, liraglutide, and semaglutide in reducing incident major adverse cardiovascular events (MACEs) among patients with both OSA and T2DM. Propensity-score matching was performed for confounders, and each treatment arm included over 7,000 patients, with 18 months of follow-up. Stratified analyses by BMI, age, sex, and ethnicity were conducted. A secondary analysis assessed incident OSA in T2DM patients treated with these agents.

Results: Tirzepatide was associated with a significantly lower risk of incident MACEs compared with liraglutide (hazard ratio [HR], 0.58; 95% confidence interval [CI], 0.51–0.66) and semaglutide (HR, 0.86; 95% CI, 0.74–0.99). The benefit was most pronounced in younger, White, male patients. Tirzepatide also reduced incident OSA compared with liraglutide (HR, 0.89; 95% CI, 0.82–0.97), but not semaglutide (HR, 0.94; 95% CI, 0.86–1.02).

Source:

Henney AE, et al. (2025, July). Ann Am Thorac Soc. Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence. https://pubmed.ncbi.nlm.nih.gov/40590655/